首页|期刊导航|中华医学杂志(英文版)|Efficacy and safety of decitabine combined with low-dose cytarabine,aclarubicin,and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation
Efficacy and safety of decitabine combined with low-dose cytarabine,aclarubicin,and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation
Si-Si Chen Qian Sun Lan Cao Wen-Zhong Wu Yue Xie Chun Qiao Jian-Yong Li Si-Xuan Qian Ming Hong
中华医学杂志(英文版)2021,Vol.134Issue(12):1477-1479,3.
中华医学杂志(英文版)2021,Vol.134Issue(12):1477-1479,3.DOI:10.1097/CM9.0000000000001316
Efficacy and safety of decitabine combined with low-dose cytarabine,aclarubicin,and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation
Efficacy and safety of decitabine combined with low-dose cytarabine,aclarubicin,and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation
摘要
引用本文复制引用
Si-Si Chen,Qian Sun,Lan Cao,Wen-Zhong Wu,Yue Xie,Chun Qiao,Jian-Yong Li,Si-Xuan Qian,Ming Hong..Efficacy and safety of decitabine combined with low-dose cytarabine,aclarubicin,and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation[J].中华医学杂志(英文版),2021,134(12):1477-1479,3.基金项目
This work was supported by the National Natural Science Foundation of China (Nos.81870119 and 81720108002),the National Science and Technology Major Project (No.2018ZX09734007),and the Clinical Medicine and Technological Development Foundation of Jiangsu Uni-versity (No.JLY20180072). (Nos.81870119 and 81720108002)